Trends in hospitalizations and mortality rates for anti-neutrophil cytoplasmic antibody-associated vasculitis in Mexico: Results from a Nationwide Health Registry
Authors:
- Ivet Etchegaray-MoralesIEIvet Etchegaray-Morales
- Claudia Mendoza-PintoCMClaudia Mendoza-Pinto
- Susana Barrera-HernándezSBSusana Barrera-Hernández
- Yolanda Martina Martínez-BarragánYMYolanda Martina Martínez-Barragán
- Pamela Munguía-RealpozoPMPamela Munguía-Realpozo
- Ingris Pelaez-BallestasIPIngris Pelaez-Ballestas
- Roberto Berra-RomaniRBRoberto Berra-Romani
- Edith Ramírez-LaraEREdith Ramírez-Lara
- Jorge Ayón-AguilarJAJorge Ayón-Aguilar
- Socorro Méndez-MartínezSMSocorro Méndez-Martínez
Preprint
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis entails substantial morbidity and mortality, yet no epidemiologic evidence exists on its outcomes in Mexico. This study assessed national hospitalizations (2005–2022) and mortality (2000–2022) related to ANCA-associated vasculitis using data from the General Board of Health Information. We extracted hospital discharges and deaths classified under ICD-10 M31.3 and M31.7, computing age-standardized hospitalization (ASHR) and mortality (ASMR) rates per 100,000 persons, overall and by sex. Annual percentage change (APC) and average annual percent change (AAPC) were estimated with Joinpoint regression. We identified 2,804 hospitalizations and 599 deaths. Females accounted for 50.3% of hospitalizations, while males represented 48.7% of deaths. Although overall ASHR and ASMR AAPCs were not statistically significant, notable trends emerged. From 2010 to 2022, ASHR declined significantly (APC: −5.2%; 95% CI: −9.7, −0.5; p=0.03), whereas mortality rates remained stable from 2000 to 2022 (AAPC: +3%; 95% CI: −4.6, 11.3; p=0.45). Nevertheless, mortality increased among males (APC: +6.4%; 95% CI: 0.9, 12.2; p=0.02) and individuals over 45 years (APC: +8.6%; 95% CI: 1.7, 16.0; p=0.02) from 2008 onward. Overall, these findings indicate no major changes in national rates, but reveal a decline in hospitalizations since 2010 and a rise in mortality for specific subgroups since 2008. Targeted interventions, particularly for older adults and men, appear warranted to address this evolving disease burden. Future research should explore underlying risk factors and evaluate tailored strategies to improve clinical outcomes in ANCA-associated vasculitis across Mexico. These insights may guide policy decisions and contribute to improved patient management nationwide.Keywords
This publication has 37 references indexed in Scilit:
- Disparities in Lupus and the Role of Social Determinants of Health: Current State of Knowledge and Directions for Future ResearchACR Open Rheumatology, 2023
- Trends in mortality in patients with systemic autoimmune rheumatic diseases (SARD) during the COVID-19 pandemic in MexicoRheumatology International, 2023
- Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014Autoimmunity Reviews, 2020
- Mexican rheumatology: where do we stand?Rheumatology International, 2018
- The complications of vasculitis and its treatmentBest Practice & Research Clinical Rheumatology, 2018
- Nomenclature of Cutaneous VasculitisArthritis & Rheumatology, 2018
- Vasculitis: do we know more to classify better?Pediatric Nephrology, 2014
- ANCA-associated vasculitis in Hispanic Americans: an unrecognized severityClinical Rheumatology, 2014
- 2012 Revised International Chapel Hill Consensus Conference Nomenclature of VasculitidesArthritis & Rheumatism, 2012
- Permutation tests for joinpoint regression with applications to cancer ratesStatistics in Medicine, 2000